Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pulse BiosciencesPLSE -0.93%30 Net Cash per Share is $1.21 as of Jun. 2026, which is 92% below its 10-year median of 14.28. GuruFocus rates PLSE with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 301 Medical Devices & Instruments companies, Pulse Biosciences ranks worse than 85.05% on this metric.
The historical rank and industry rank for Pulse Biosciences's Net Cash per Share or its related term are showing as below:
PLSE'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.27 Med: 14.28 Max: 293.28
Current: 36.8
During the past 12 years, the highest Price-to-Net-Cash Ratio of Pulse Biosciences was 293.28. The lowest was 4.27. And the median was 14.28.
PLSE's Price-to-Net-Cash is ranked worse than 85.05% of 301
companies
in the Medical Devices & Instruments industry
Industry Median: 9.73
vs PLSE: 36.80
Pulse Biosciences (NAS:PLSE) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Pulse Biosciences Net Cash per Share Related Terms
Pulse Biosciences Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Pulse Biosciences's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PLSE vs LMAT, ATRC, XRAY: Net Cash per Share Comparison
For the Medical Instruments & Supplies subindustry, Pulse Biosciences's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulse Biosciences Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Pulse Biosciences's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Pulse Biosciences's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulse Biosciences (PLSE) has a Net Cash per Share of $1.21 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Pulse Biosciences and its competitors. This is 92% below median its historical median of 14.28. Over the past decade, Pulse Biosciences' Net Cash per Share has ranged from 4.27 to 293.28. According to the industry distribution chart, Pulse Biosciences ranks #256 out of 301 companies in the Medical Devices & Instruments industry, placing it in the top 85%.
Is Pulse Biosciences' Net Cash per Share too high?
Pulse Biosciences' current Net Cash per Share of $1.21 is 92% below median its 10-year median of 14.28. Over the past 10 years, this metric has ranged from a low of 4.27 to a high of 293.28. The Medical Devices & Instruments industry median Net Cash per Share is 9.73. Pulse Biosciences' value of $1.21 is 87.6% below this industry median. Based on the distribution chart, Pulse Biosciences ranks #256 out of 301 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Pulse Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Pulse Biosciences' Net Cash per Share compare to LMAT and ATRC?
According to the Medical Devices & Instruments industry distribution chart, Pulse Biosciences ranks #256 out of 301 companies for Net Cash per Share. This places Pulse Biosciences in the lower half of its industry. The industry median Net Cash per Share is 9.73. Pulse Biosciences' value of $1.21 is 87.6% below this benchmark. Historically, Pulse Biosciences' own Net Cash per Share has ranged from 4.27 to 293.28 over the past decade. While the company's 10-year median is 14.28 vs. the industry median of 9.73, Pulse Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 9.73, based on 301 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pulse Biosciences's current Net Cash per Share of $1.21 is 87.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Pulse Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 9.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulse Biosciences's current Net Cash per Share is $1.21, which is 92% below median its own 10-year median of 14.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulse Biosciences stock overvalued right now?
Pulse Biosciences (PLSE) has a current Net Cash per Share of $1.21. The current Net Cash per Share is $1.21, which is 92% below median its 10-year median of 14.28 and 87.6% below the Medical Devices & Instruments industry median of 9.73. Pulse Biosciences' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Pulse Biosciences (PLSE), the current Net Cash per Share is $1.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
30GF Score
Get the complete analysis for PLSE
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSE has been successfully added to your 
